Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71820 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.04.2026. Verfasst von Kento Morozumi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tohoku Medical and Pharmaceutical University, Miyagi, Japan. Hauptthemen laut MEDLINE: Prostatectomy, Cytoreduction Surgical Procedures, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Local therapy for metastatic castration‐sensitive prostate cancer (mCSPC) remains controversial. This study aimed to assess the feasibility, safety, and oncologic outcomes of cytoreductive radical prostatectomy (cRP) in patients with synchronous mCSPC, with a particular focus on pathological findings.
Method
We retrospectively analyzed 61 patients with mCSPC who underwent cRP following neoadjuvant androgen deprivation therapy (ADT). Clinical, perioperative, and pathological parameters were reviewed. Survival outcomes were assessed in relation to biopsy Gleason grade (GG), metastatic burden, PSA dynamics, and pathological treatment effect (pTE).
Results
The 5‐year CRPC‐free survival and cancer‐specific survival (CSS) rates were 50.8% and 77.0%, respectively. Biopsy GG 5 was associated with adverse outcomes, whereas pTE grade ≥ 2 was significantly associated with favorable outcomes, including improved CSS. Biopsy GG 5 was the sole preoperative factor associated with pTE. The rate of major perioperative complications (Clavien–Dindo grade ≥ 3) was 1.6%, underscoring the safety of cRP in this setting.
Conclusion
Cytoreductive radical prostatectomy (cRP) appears to be a feasible and safe local treatment option in selected patients with mCSPC. In addition to cytoreductive benefit, cRP provides critical pathological information—particularly pTE—that correlates strongly with survival outcomes but cannot be predicted preoperatively. These findings support the incorporation of cRP as a diagnostic and therapeutic component within a multimodal treatment strategy for mCSPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
- Department of Urology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
ORCID-Profile: Kento Morozumi, Yasuhiro Kaiho
Zitieren
APA
Morozumi, K., Numahata, K., Oikawa, M., Konno, M., Kusumoto, H., Akito, K., Katsumata, Y., Sato, M., & Kaiho, Y. (2026). Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71820
Vancouver
Morozumi K, Numahata K, Oikawa M, Konno M, Kusumoto H, Akito K, et al. Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71820
BibTeX
@article{Morozumi2026,
author = {Morozumi, Kento and Numahata, Kenji and Oikawa, Masaaki and Konno, Masato and Kusumoto, Hiroki and Akito, Kuromoto and Katsumata, Yuki and Sato, Masahiko and Kaiho, Yasuhiro},
title = {Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71820}
}
EUVIMED